Clinical trials: Vorinostat
Malignant Solid Tumour
Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer
This is a multi-center, open-label non-randomized dose-escalation trial of vorinostat given in combination with vinorelbine. Cohorts will be treated with a fixed dose of vinorelbine (25mg/m²/week continuously, representing the…
- Trial name
- NCT00801151
- Testing
- Zolinza (vorinostat), vinorelbine
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- Institut Claudius Regaud
Multiple Myeloma
A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
This study will evaluate the feasibility of combining four of the most active agents available for the treatment of multiple myeloma. Further the investigators will attempt to assess the activity of this combination.
- Trial name
- QUAD (NCT01297764)
- Testing
- Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Hackensack Meridian Health
Pelvic Cancer, Radiotherapy
Vorinostat and Palliative Radiotherapy
Phase I study. Side-effects when combined with standard palliative radiotherapy.
- Trial name
- PRAVO (NCT00455351)
- Testing
- Vorinostat
- Where
- Norway
- Volunteers
- 15 people
- Sponsor
- Oslo University Hospital
Unspecified Adult Solid Tumor, Protocol Specific
Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors
This phase I trial is studying the side effects and best dose of vorinostat when given together with doxorubicin in treating patients with metastatic or locally advanced solid tumors.
- Trial name
- NCT00331955
- Testing
- doxorubicin hydrochloride, vorinostat, pharmacological study
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia With 11q23-abnormality in Relapse
Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)
The purpose of the study is to first determine if temozolomide plus vorinostat in combination can control relapsed or refractory acute myeloid leukemia (AML) and determine if this combination can be safely taken.
- Trial name
- NCT01550224
- Testing
- Temozolomide, Vorinostat
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Steven E. Coutre
Unspecified Adult Solid Tumor, Protocol Specific
Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors
This phase I trial is studying the side effects and best dose of vorinostat when given together with paclitaxel and carboplatin in treating patients with advanced or refractory solid tumors.
- Trial name
- NCT00287937
- Testing
- vorinostat, paclitaxel, carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Small Intestine Cancer
Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
RATIONALE: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth, and may stimulate the immune system to stop cancer cells from growing.
- Trial name
- NCT00561418
- Testing
- vorinostat, Correlative studies
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase I trial is studying the side effects and best dose of vorinostat when given together with bortezomib in treating patients with relapsed or refractory multiple myeloma.
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00310024
- Testing
- bortezomib, vorinostat, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed Lymphomas, Refractory Lymphomas
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
The study will be a dose-finding, phase I study of the combination of vorinostat and PLD in patients with advanced lymphoma refractory to at least one prior systemic therapy.
- Trial name
- NCT00785798
- Testing
- Vorinostat, Pegylated Liposomal Doxorubicin (PLD), Doxil
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Yale University
Children With Relapsed Solid Tumor, Lymphoma or Leukemia
Vorinostat in Children
The aim of this study is to define a dose recommendation of vorinostat in pediatric oncology, to determine pharmacokinetics of vorinostat in children, determine response rates, safety and feasibility.
- Trial name
- NCT01422499
- Testing
- zolinza/vorinostat
- Where
- 10 sites in Germany
- Volunteers
- 50 people
- Sponsor
- National Center for Tumor Diseases, Heidelberg
Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
This phase I trial studies the side effects and the best dose of cytarabine when given together with decitabine and vorinostat in treating patients with acute myeloid leukemia or myelodysplastic syndrome that has returned or has…
- Conditions
- Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
- Trial name
- NCT01130506
- Testing
- Cytarabine, Decitabine, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Male Breast Cancer, Recurrent Breast Cancer
Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing or by stopping them from spreading.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT01084057
- Testing
- vorinostat, ixabepilone, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma and Plasma Cell Neoplasm
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Vorinostat and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Bortezomib may also stop the growth of multiple myeloma by blocking blood flow to the tumor.
- Trial name
- NCT00744354
- Testing
- bortezomib, pegylated liposomal doxorubicin hydrochloride, vorinostat
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Advanced Cancer
Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies
The goal of this clinical research study is to find the highest tolerable dose of the combination of pazopanib and vorinostat that can be given to patients with advanced cancer.
- Trial name
- NCT01339871
- Testing
- Pazopanib, Vorinostat
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- M.D. Anderson Cancer Center
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML
The purpose of this study is to test the safety of vorinostat (Zolinza) and azacitidine (Vidaza) when combined with gemtuzumab ozogamicin (GO) at different dose levels.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT00895934
- Testing
- vorinostat, gemtuzumab ozogamicin, azacitidine
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
The goal of this clinical research study is to learn if the combination of azacitidine and vorinostat can help to control AML or MDS better than azacitidine alone. The safety of this drug combination will also be studied.
- Trial name
- NCT00948064
- Testing
- Vorinostat, Azacitidine
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myelogenous Leukemia
Epigenetic Reprogramming in Relapse/Refractory AML
This is a pilot study using decitabine and vorinostat before and during chemotherapy with fludarabine, cytarabine and G-CSF (FLAG).
- Trial name
- NCT03263936
- Testing
- Decitabine, Vorinostat, Filgrastim (G-CSF)
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 37 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Recurrent Glioblastoma Multiforme, Malignant Glioma
Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
It has been shown that bevacizumab has significant anti-tumor activity in patients with recurrent glioblastoma multiforme. Vorinostat has modest anti-tumor activity against malignant glioma and can enhance the action of both…
- Conditions
- Recurrent Glioblastoma Multiforme, Malignant Glioma, Adult Brain Tumor
- Trial name
- NCT01738646
- Testing
- Vorinostat, Bevacizumab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Duke University
Multiple Myeloma
Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy
Histone deacetylase (HDAC) inhibitors represent a potential new class of antitumor agents. Vorinostat (suberoylanilide Hydroxamic acid, SAHA) inhibits the activity of all 11 known human class I and II HDACs.
- Trial name
- ZLd_Ld (NCT01501370)
- Testing
- Vorinostat, Lenalidomide, Dexamethasone
- Where
- 8 sites in Italy
- Sponsor
- Tiziana Marangon
Myeloma
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
The goal of this clinical research study is to learn if carfilzomib and vorinostat combined with gemcitabine, busulfan, and melphalan with a stem cell transplant will help to control multiple myeloma (MM).
- Trial name
- NCT02114502
- Testing
- Carfilzomib, SAHA, Gemcitabine
- Sponsor
- M.D. Anderson Cancer Center